Nov 18 (Reuters) - Roche Holding AG:
* ROCHE TO PRESENT NEW AND UPDATED DATA FOR SEVEN APPROVED AND INVESTIGATIONAL MEDICINES ACROSS MULTIPLE TYPES OF BREAST CANCER AT THE 2019 SAN ANTONIO BREAST CANCER SYMPOSIUM
* STUDY RESULTS REFLECT ADVANCEMENTS IN HER2-POSITIVE, TRIPLE-NEGATIVE, AND HORMONE RECEPTOR-POSITIVE BREAST CANCER
* FOLLOW-UP DATA FROM PIVOTAL PHASE III APHINITY STUDY EVALUATING PERJETA PLUS HERCEPTIN AND CHEMOTHERAPY IN HER2-POSITIVE EARLY BREAST CANCER
* RESULTS FROM PHASE III FEDERICA STUDY CONFIRMING NON-INFERIORITY OF A FIXED-DOSE COMBINATION OF PERJETA AND HERCEPTIN ADMINISTERED UNDER SKIN Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)
